Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

A single-arm intervention study in Japanese adults with moderate chronic kidney disease found that replacing breakfast with ...

MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence ...

This population-based study used plasma pTau217 to estimate how common Alzheimer’s disease neuropathological changes are across age and cognitive status in a Norwegian community cohort. Prevalence ...

Important Safety Information Indication Elfabrio ® (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed ...

Elfabrio (R) (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed diagnosis of Fabry disease (deficiency of ...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ha ...

The discovery of TFA in blood and water samples raises questions about Chemours’ role in adding to the pollution burden.

Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 ...

The discovery of TFA in blood and water samples raises questions about Chemours’ role in adding to the pollution burden.

Living kidney donations can be a better match, reducing the risk of organ rejection. They allow for surgery to be planned for ...

Moreno is part of a pilot program with 15 patients that began in May at three Pennsylvania hospitals. It's testing whether ...